Novogen (NASDAQ:KZIA) & Opthea (NASDAQ:OPT) Head to Head Analysis

Novogen (NASDAQ:KZIA) and Opthea (NASDAQ:OPT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ownership and dividends.

Institutional and Insider Ownership

30.9% of Novogen shares are owned by institutional investors. Comparatively, 56.0% of Opthea shares are owned by institutional investors. 1.0% of Novogen shares are owned by insiders. Comparatively, 3.2% of Opthea shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Novogen and Opthea”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novogen	$30,000.00	550.00	-$13.41 million	N/A	N/A
Opthea	$25,000.00	20,993.46	-$162.79 million	N/A	N/A

Novogen has higher revenue and earnings than Opthea.

Volatility & Risk

Novogen has a beta of 1.67, indicating that its stock price is 67% more volatile than the S&P 500. Comparatively, Opthea has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500.

Profitability

This table compares Novogen and Opthea’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Novogen	N/A	N/A	N/A
Opthea	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Novogen and Opthea, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novogen	1	0	2	0	2.33
Opthea	2	4	0	0	1.67

Novogen presently has a consensus price target of $19.00, suggesting a potential upside of 90.00%. Opthea has a consensus price target of $1.33, suggesting a potential downside of 60.90%. Given Novogen’s stronger consensus rating and higher probable upside, equities analysts plainly believe Novogen is more favorable than Opthea.

Summary

Novogen beats Opthea on 6 of the 9 factors compared between the two stocks.

About Novogen

Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company’s lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

About Opthea

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.